For important risk and disclaimer information, Click here.

Industry

Healthcare

Company Type

Biotechnology/Life Sciences

Size

$15 Million

Investment Type

Debt

For additional information, please contact:
Gary Levy | Managing Director
(516) 457-0104

Overview

The Company is a successful 10-year-old mRNA Medicines platform raising $15 million through a convertible debenture offering ($1.5 million already secured/committed), which will fund an advancing mRNA personalized cancer program in 2025.

Debenture is offered at a 10% coupon. On Series B close, investors can decide on cash or conversion with 10% discount and conversion ceiling at $12 per share.

  • Advancing cancer treatment with mRNA-based vaccines and an effective proprietary LNP delivery platform technology, which is attracting significant interest from new partners

 

  • This LNP technology, combined with cancer vaccines developed through its unique academic partnership platform model, has positioned Providence to begin a number of Nof1 human trials for personalized mRNA vaccines in 2025 in both Canada and Australia

 

  • This will assist in fast tracking the company’s mRNA cancer vaccines to commercialization

 

  • Novel approach to funding, accessing human capital, accelerating development, and forming strategic partnerships to access its unique internally developed intellectual property

 

  • Led by a management team with deep expertise and prior successful biotech startup experience

Opportunity

  • The Oncology vaccine market is an emerging market with significant growth prospects due to new technology such as mRNA which previously proved effective in resolving infectious disease such as COVID2

 

  • mRNA based oncology treatment has not yet been approved or advanced to the drug commercialization stage anywhere in the world, primarily due to challenges associated with delivery of the medicine to cancer cells within patients3

 

  • Lipid nanoparticle (“LNP”) technology provides the most effective means of delivering mRNA vaccine treatment to patients. Access to effective LNP delivery systems is tightly controlled by large biopharma, presenting barriers to entry to market for those in developing effective mRNA cancer treatments

 

  • Advances in lipid nanoparticle technology and the advent of personalized cancer therapies provide exciting opportunities to participate in the discovery and advancement of effective treatment of cancers through mRNA therapies

 

  • In Canada and Australia the drug development process through human Nof1 compassionate use trials can be fast tracked

 

2Cancer mRNA vaccines: clinical advances and future opportunities | Nature Reviews Clinical Oncology and mRNA Therapeutics Market Size And Share Report, 2030

3Clinical advances of mRNA vaccines for cancer immunotherapy – ScienceDirect

10 Years of Science and Innovation in mRNA

The Company has an End-to-End mRNA Medicines Platform to Develop

 

Vaccines and Therapeutics

Clinically Proven mRNA Platform

™ Oncology

 

mRNA Encapsulated with™ Oncology Elicited Superior Tumor Control in the MC38-gp Tumor Mouse Model

Potential mRNA and LNP Commercial Partnership

Specific Risks

  • High Burn Rate: Biotech startups require significant funding for R&D, clinical trials, and regulatory approvals

 

  • Dilution Risk: Raising capital through equity financing can dilute existing shareholders

 

  • Exit Uncertainty: IPOs or acquisitions are not guaranteed, and investors may struggle to achieve profitable exits

 

  • Regulatory Hurdles: Approval from regulatory bodies (FDA, EMA, Health Canada) is complex, lengthy, and uncertain

 

  • Clinical Trial Failures: High risk of failing to meet safety and efficacy endpoints in different trial phases

 

  • Changing Regulations: Global biotech regulations evolve, requiring adaptation and potential cost increases

 

  • Intellectual Property (IP) Risks: Patents can be challenged, or competitors may develop similar therapies, reducing market exclusivity

 

  • Management & Operational Risks Talent Acquisition & Retention: Recruiting top scientific and executive talent is highly competitive and expensive

 

  • Operational Bottlenecks: Scaling from R&D to commercial production can introduce unforeseen challenges

 

  • Market Adoption Challenges: Even if approved, a drug may not be widely adopted by physicians or insurers

 

  • Reimbursement & Pricing Pressures: Government and insurance reimbursement policies can limit profitability

 

  • Competition: Larger pharmaceutical companies may develop competing treatments or acquire competitors

 

  • Manufacturing & Scaling Issues: Producing biologics, gene therapies, or mRNA-based treatments at scale can be technically complex and expensive

 

  • Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
Learn More About Providence Therapeutics

Thank you for your interest in Providence Therapeutics.

Please fill out your information and we will contact you shortly with more information on this opportunity.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending